Format

Send to

Choose Destination
See comment in PubMed Commons below
MAbs. 2012 Mar-Apr;4(2):256-66. doi: 10.4161/mabs.4.2.19136. Epub 2012 Mar 1.

Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.

Author information

  • 1State Key Laboratory of Oncology in Southern China; Sun Yat-Sen University; Guangzhou, Guangdong, China; Department of Clinical Trial Center; Cancer Center; Sun Yat-sen University; Guangzhou, Guangdong, China.
  • 2State Key Laboratory of Oncology in Southern China; Sun Yat-Sen University; Guangzhou, Guangdong, China; Department of Medical Oncology; Cancer Center; Sun Yat-Sen University; Guangzhou, Guangdong, China.

Abstract

The safety and pharmacokinetics assessment of antibodies targeting CD22 (e.g., epratuzumab) have been established in western Caucasian populations, but there are no reports of the effects in Chinese populations. This dose-escalation study examines the safety, pharmacokinetics and biologic effects of multiple doses of anti-CD22 human-murine chimeric monoclonal antibody SM03 in 21 Chinese patients with CD22-positive non-Hodgkin lymphoma. Most of drug-related adverse events (AEs) were mild and reversible. Two patients experienced serious AEs (hemorrhage); one patient had grade 4 neutropenia; one patient had asymptomatic grade III prolongation of activated partial thromboplastin time (APTT). Major AEs included fever (71%), prolongation of APTT (42.8%), leukocytopenia (44.4%), alanine transaminase elevation (28.6%), elevated serum creatinine (23.8%) and injection site skin redness (14.3%). Circulating B cells transiently decreased without significant effects on T cells or immunoglobulin levels. Pharmacokinetic data revealed that mean maximum observed SM03 concentration and mean AUC from time zero to infinity increased in a dose-dependent manner up to 360 mg/m (2) SM03. Mean clearance was similar at doses ≤ 360 mg/m (2) and decreased significantly at dose 480 mg/m (2), supporting saturation of B-cell binding at 360 mg/m (2). Across all dose levels and histologies, one patient achieved partial response at 480 mg/m (2) dose; 14 patients had stable disease as best response and four patients progressed. Overall, SM03 was tolerated at doses ranging from 60-480 mg/m (2) and had potential efficacy in Chinese patients with follicular lymphoma.

KEYWORDS:

anti-CD22 monoclonal antibody; pharmacokinetics; tolerance

PMID:
22453099
PMCID:
PMC3361661
DOI:
10.4161/mabs.4.2.19136
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center